Company · BMRN
BioMarin
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
8
8 still marketed
Novel approvals
7
Approvals since 2021
4
Originals and new uses
Phase 3 trials
27
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Palynziq new use Priority reviewOrphanFeb 27, 2026
- Brineura new use OrphanJul 24, 2024
- Voxzogo new use OrphanOct 20, 2023
- Voxzogo approved NovelAccelerated approvalOrphanNov 19, 2021
- Palynziq new use OrphanOct 6, 2020
- Palynziq new use OrphanOct 6, 2020
- Palynziq new use OrphanOct 6, 2020
- Palynziq approved NovelPriority reviewOrphanMay 24, 2018
- Brineura approved NovelPriority reviewOrphanApr 27, 2017
- Kuvan new use Priority reviewOrphanApr 23, 2014
Drugs in development (5)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- Modified recombinant human C-type natriuretic peptideBMN 111Phase 32 trials
BioMarin · Achondroplasia
- Valoctocogene roxaparvovecBMN 270, GENEr8Phase 32 trials
BioMarin · Hemophilia A, Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
- BMN 333Phase 31 trial
BioMarin · Achondroplasia
- BMN 351Phase 22 trials
BioMarin · Duchenne Muscular Dystrophy (DMD), Duchenne Muscular Dystrophy
- BMN 307Phase 21 trial
BioMarin · Phenylketonuria (PKU)
Recruiting Phase 3 trials
Largest first.
- Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaPivotal-lookingRecruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT07441876 · 160 participants (planned) · Start Apr 20, 2026 · Primary completion Jun 2029
Drug: BMN 333; Vosoritide Injection [Voxzogo] · For: Achondroplasia
Sites: Oakland, California; Wilmington, Delaware; Chicago, Illinois · 28 sites in all
Marketed drugs (8)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.